Trials / Completed
CompletedNCT00124436
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Follow up Efficacy and Safety Study of BAL4979 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Basilea Pharmaceutica · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | alitretinoin |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2007-01-01
- Completion
- 2007-02-01
- First posted
- 2005-07-28
- Last updated
- 2023-05-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00124436. Inclusion in this directory is not an endorsement.